Growth failure and bony changes induced by deferoxamine.
We reviewed the linear growth and growth plate morphology in all children with homozygous beta thalassemia followed in Toronto, for whom monthly height percentiles were available before, and for a 36-month period after, the initiation of nightly subcutaneous deferoxamine therapy. All patients were less than 7 years of age when begun on deferoxamine, and had received nightly deferoxamine for a minimum of 36 months. Marked abnormalities of the metaphyseal growth plate were readily observed in the distal ulnar, radial, and tibial metaphyses in 11 of 37 patients in whom a significant decline in mean height percentile was also noted. (In 10 of these 11 patients, height was less than the 15th percentile after 36 months.) These 11 patients had received a significantly greater (p less than 0.025) initial and average daily dose of deferoxamine, and had maintained a significantly lower (p less than 0.025) mean serum ferritin concentration over the 36 months, than the remainder of the cohort. To determine whether deferoxamine played a causative role in growth failure, growth in patients who began deferoxamine before the age 2 years was compared to that of patients who began after age 5 years, for the period between 2 and 5 years of age. Only patients begun on deferoxamine prior to age 2 years demonstrated a significant (p less than 0.01) decline in height percentile by the third year, implicating deferoxamine therapy as the cause of growth failure. We conclude that both the decline in height percentile and the bony changes observed in well-chelated patients are directly related to deferoxamine therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
Olivieri
N F
NF
Division of Haematology/Oncology, Hospital for Sick Children, University of Toronto, Ontario, Canada.
Koren
G
G
Harris
J
J
Khattak
S
S
Freedman
M H
MH
Templeton
D M
DM
Bailey
J D
JD
Reilly
B J
BJ
D000469:Alkaline Phosphatase / Q000097:blood; D001827:Body Height / Q000187:drug effects; D001846:Bone Development / Q000187:drug effects*; D002675:Child, Preschool; D003676:Deferoxamine / Q000009:adverse effects*; D006132:Growth Plate / Q000000981:diagnostic imaging / Q000187:drug effects*; D006801:Humans; D011859:Radiography; D012307:Risk Factors; D013789:Thalassemia / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D014131:Trace Elements / Q000097:blood
D014131:Trace Elements; D000469:Alkaline Phosphatase; D003676:Deferoxamine